Table 1.

Patient demographics and baseline disease characteristics (randomized set)

	Placebo (N = 157)	CZP 200 mg Q2W † (N = 351)	CZP 400 mg Q2W (N = 342)
Demographics
Age (years), mean ± SD	46.0 ± 13.3	46.1 ± 13.4	45.2 ± 12.6
Male, n (%)	95 (60.5)	238 (67.8)	210 (61.4)
White, n (%)	146 (93.0)	331 (94.3)	322 (94.2)
Geographic region, n (%)
North America	71 (45.2)	136 (38.7)	133 (38.9)
Europe	86 (54.8)	215 (61.3)	209 (61.1)
Weight (kg), mean ± SD	92.2 ± 25.8	92.6 ± 22.3	89.2 ± 22.7
BMI (kg/m2), mean ± SD	31.2 ± 7.8	31.0 ± 7.1	30.1 ± 7.1
Baseline disease characteristics
Duration of psoriasis at screening (years), mean ± SD	17.7 ± 12.7	18.5 ± 13.1	18.2 ± 12.0
Concurrent psoriatic arthritis (self‐reported), n (%)	25 (15.9)	59 (16.8)	65 (19.0)
PASI, mean ± SD	18.8 ± 6.8	20.3 ± 8.1	20.2 ± 7.5
DLQI ‡ mean ± SD	13.4 ± 7.7	13.6 ± 7.2	14.5 ± 7.1
BSA (%), mean ± SD	23.5 ± 13.6	25.6 ± 15.9	25.5 ± 14.9
PGA, n (%)
3: moderate	112 (71.3)	242 (68.9)	239 (69.9)
4: severe	45 (28.7)	109 (31.1)	103 (30.1)
Any prior systemic psoriasis treatment, n (%)	111 (70.7)	249 (70.9)	247 (72.2)
Prior biologic use § n (%)	40 (25.5)	106 (30.2)	107 (31.3)
Anti‐TNF	24 (15.3)	49 (14.0)	43 (12.6)
Anti‐IL‐17	13 (8.3)	54 (15.4)	43 (12.6)

^†CZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2 and 4. ^‡For DLQI: Placebo, N = 154; CZP 200 mg Q2W, N = 346; CZP 400 mg Q2W, N = 340. ^§Patients may have had exposure to >1 prior biologic but ≤2 per exclusion criteria; one patient in the CZP 400 mg Q2W group in CIMPASI‐2 had prior exposure to three biologics, which was a protocol violation.

BMI, body mass index; BSA, body surface area; CZP, certolizumab pegol; DLQI, Dermatology Life Quality Index; IL, interleukin; PASI, psoriasis area and severity index; PGA, physician's global assessment; Q2W, every 2 weeks; TNF, tumour necrosis factor.